Malignant News and Research

RSS

Research on safety of endoscopic piecemeal mucosal resection in treatment of large sessile colorectal polyps

Endoscopic resection of large sessile colorectal polyps is increasingly used as an alternative to surgery, but remains challenging because of its technical difficulty, the high risk of complications such as bleeding or perforation, and the possibility of coexisting malignancy.

25 Jun 2010

Japanese researchers identity useful markers for early diagnosis of CMV gastritis

Cytomegalovirus (CMV) disease is a serious complication after allogeneic hematopoietic stem cell transplantation (allo-SCT), which is widely accepted as a curative therapy for advanced hematological malignancies including leukemia and malignant lymphoma.

25 Jun 2010

New book provides comprehensive review of the functions of p53 family

The p53 tumor suppressor gene, the "guardian of the genome," protects cells against genotoxic stress but is mutated in many cancers. It encodes one of a family of proteins that regulate cell proliferation, differentiation, senescence, and cell death. Mutations in p53 allow cells to escape normal growth controls and thereby contribute to tumor malignancy.

24 Jun 2010

USPTO confirms validity of DUSA's key Levulan PDT patent

DUSA Pharmaceuticals, Inc.®, a dermatology company that is developing and marketing Levulan® Photodynamic Therapy (PDT), today announced that the United States Patent and Trademark Office (USPTO) has completed its re-examination of US Patent No. 5,079,262, "Method of detection and treatment of malignant and non-malignant lesions utilizing 5-aminolevulinic acid."

24 Jun 2010

Michigan State University researchers analyze histiocytic sarcomas

Michigan State University veterinarians are taking part in a two-year, $5.3 million project to analyze five cancers in dogs, research that could offer new insight into canine cancer genes and their potential impact on the human form of the disease.

22 Jun 2010

Ultrasound-guided diffuse optical tomography holds promise for ascertaining early-stage invasive breast cancer

By combining two relatively inexpensive technologies based on sound and light waves, researchers hope to lower the rate at which women undergo breast biopsies for suspicious lesions. Results of the study on ultrasound-guided optical tomography are published in the online edition and the August print issue of Radiology.

22 Jun 2010

Naviscan announces presentations on PEM technology at Society of Nuclear Medicine Annual Meeting

Naviscan's Positron Emission Mammography (PEM) technology was the focus of several presentations and discussions at the Society of Nuclear Medicine Annual Meeting in Salt Lake City. The focus represents a growing interest and validation of how PEM can play an important role in the fight against breast cancer.

18 Jun 2010

Pelvic extraperitoneal IMT with malignant transformation in 14-year-old

Inflammatory myofibroblastic tumor (IMT) is an uncommon benign neoplasm with locally aggressive behavior but malignant change is rare. Such a rare tumor occurring in a 14-year-old patient with clinical presentations of abdominal pain and body weight loss was seldom described before.

18 Jun 2010

VCU researchers discover mechanism that regulates gene expression and growth in melanoma cells

Virginia Commonwealth University researchers have discovered a mechanism by which an enzyme regulates gene expression and growth in melanoma cells, a finding that could someday lead to more effective drugs to attack cancers and make them more treatable.

18 Jun 2010

TechniScan launches clinical study of Warm Bath Ultrasound system in Rochester

TechniScan, a medical device company engaged in the development and commercialization of an automated 3D breast ultrasound imaging system, today announced that it has launched a clinical study in Rochester, Minn., its third new clinical site to commence in the last five months.

17 Jun 2010

Clinical trial to examine use of biomarkers to advance treatment of malignant gliomas launched

The Brain Tumor Unit at the Moores UCSD Cancer Center at the University of California, San Diego in La Jolla, is launching a clinical trial that will examine the use of biomarkers to advance the treatment of malignant gliomas, brain tumors that start in the brain or spinal cord tissue. Annually, about 17,000 Americans are diagnosed with gliomas, which are difficult to treat and often fatal.

16 Jun 2010

Fluorescent cancerous tumors for early detection

Researchers at the Ecole Polytechnique F-d-rale de Lausanne (EPFL) in Switzerland have established a procedure where cancerous tumors in the bladder become fluorescent and are more easily discoverable under blue light. The Food and Drug Administration (FDA) approved the technique- already in practice in Europe - for the American market. Under the name Cysview-, the product is commercialized by Photocure and GE Healthcare as the most efficient detection technique for early stage bladder cancer.

14 Jun 2010

Nurse with enhanced clinical skills detects same breast abnormalities as surgeon

UK researchers have developed an Initiative that could help hospitals prevent delays to the two-week cancer target, following the reduction in junior doctors' working hours due to the European Working Time Directive. A specially trained nurse practitioner and consultant breast surgeon who examined 126 women referred to a symptomatic breast disease clinic picked up the same breast abnormalities in 92% of cases.

14 Jun 2010

Genetic variation can predict how people infected with hepatitis C react to treatment: Scientists

A small genetic change can predict how people infected with hepatitis C react to treatment, paving the way to personalised therapy for this difficult to treat disease, the annual conference of the European Society of Human Genetics will hear today (Sunday 13 June). Dr. Zoltan Kutalik, from the Department of Medical Genetics, University of Lausanne, Switzerland, will tell delegates that individuals with this change, in a gene encoding for the antiviral cytokine (cell-signalling molecule) interferon lamda, reacts less well to treatment.

14 Jun 2010

Report highlights deprivation gap caused by late diagnosis of cancer, differences in treatment choices

There could be as many as 14,000 fewer cases of cancer each year in England if everyone was as healthy as the richest 20 per cent in the country. And the difference between the classes is more marked among men than women. Among men there were 21 per cent more cases of cancer in the most deprived areas compared to the least deprived, whereas the gap among women was 11 per cent.

14 Jun 2010

Emerging science of epigenetics offers new insights at crossroads of genes and the environment: Article

An emerging arm of molecular biology is introducing a new interpretation of traditional concepts of human disease, explains an article published today in Nature. According to author Dr. Arturas Petronis at the Centre for Addiction and Mental Health, the emerging science of epigenetics is offering new insights at the crossroads of genes and the environment, or nature and nurture. Dr. Petronis is head of the Krembil Family Epigenetics Laboratory at CAMH and an international expert in the field.

11 Jun 2010

Abraxis BioScience presents phase 3 trial data on metastatic malignant melanoma

Abraxis BioScience, Inc. presented trial design information from its ongoing phase 3 registration trial of nanoparticle albumin bound (nab®) driven chemotherapy, nab-paclitaxel (ABRAXANE® for Injectable Suspension; paclitaxel albumin protein-bound particles for injectable suspension), in melanoma, an aggressive form of skin cancer that affects more than 68,000 people in the U.S. each year.

11 Jun 2010

Non-melanoma skin cancer is potential marker for survivors at risk for future malignant tumors

Childhood cancer survivors diagnosed later with non-melanoma skin cancer may be at increased risk for having a malignant tumor within 15 years, according to research led by St. Jude Children's Research Hospital investigators.

10 Jun 2010

Aeterna Zentaris reports final results on clinical activity of perifosine for metastatic colorectal cancer

Aeterna Zentaris Inc., a late-stage drug development company specialized in oncology and endocrine therapy, today reported final results on the clinical activity of perifosine (KRX-0401), the Company's novel, potentially first-in-class, oral anticancer agent that inhibits Akt activation in the phosphoinositide 3-kinase pathway, in combination with capecitabine (Xeloda) as a treatment for advanced, metastatic colorectal cancer.

10 Jun 2010

Veracyte announces completion of Series B round

Veracyte, Inc. announced today the successful completion of its Series B round, a key milestone toward the company's first product launch later this year. The South San Francisco biotechnology company is committed to pioneering molecular cytology diagnostics to improve patient care and lower health care costs. This round was led by Domain Associates with significant participation from Veracyte's founding investors including Kleiner Perkins Caufield & Byers (KPCB), TPG Biotech (TPG), and Versant Ventures.

10 Jun 2010

Malignant News and Research

Research on safety of endoscopic piecemeal mucosal resection in treatment of large sessile colorectal polyps

Japanese researchers identity useful markers for early diagnosis of CMV gastritis

New book provides comprehensive review of the functions of p53 family

USPTO confirms validity of DUSA's key Levulan PDT patent

Michigan State University researchers analyze histiocytic sarcomas

Ultrasound-guided diffuse optical tomography holds promise for ascertaining early-stage invasive breast cancer

Naviscan announces presentations on PEM technology at Society of Nuclear Medicine Annual Meeting

Pelvic extraperitoneal IMT with malignant transformation in 14-year-old

VCU researchers discover mechanism that regulates gene expression and growth in melanoma cells

TechniScan launches clinical study of Warm Bath Ultrasound system in Rochester

Clinical trial to examine use of biomarkers to advance treatment of malignant gliomas launched

Fluorescent cancerous tumors for early detection

Nurse with enhanced clinical skills detects same breast abnormalities as surgeon

Genetic variation can predict how people infected with hepatitis C react to treatment: Scientists

Report highlights deprivation gap caused by late diagnosis of cancer, differences in treatment choices

Emerging science of epigenetics offers new insights at crossroads of genes and the environment: Article

Abraxis BioScience presents phase 3 trial data on metastatic malignant melanoma

Non-melanoma skin cancer is potential marker for survivors at risk for future malignant tumors

Aeterna Zentaris reports final results on clinical activity of perifosine for metastatic colorectal cancer

Veracyte announces completion of Series B round

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News